[Skip to Content]
[Skip to Content Landing]
Views 748
Citations 0
Comment & Response
March 26, 2014

Antithrombotic Therapy After Transcatheter Aortic Valve Replacement

Author Affiliations
  • 1Veterans Affairs Medical Center, West Palm Beach, Florida
JAMA. 2014;311(12):1249-1250. doi:10.1001/jama.2014.1180

To the Editor A solid evidence base for appropriate antithrombotic therapy in patients with complex transcatheter aortic valve replacement (TAVR) is not yet established. This is especially important because approximately 40% of patients with TAVR from both the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) registry1 and the Placement of Aortic Transcatheter Valves (PARTNER) trial2 cohorts had baseline diagnosis of atrial fibrillation (AF) and may have had an indication for anticoagulation in addition to the protocol-directed 6 months of dual antiplatelet therapy (clopidogrel and aspirin) after TAVR.

First Page Preview View Large
First page PDF preview
First page PDF preview